enGene Therapeutics (ENGN) Other Accumulated Expenses (2023 - 2026)
enGene Therapeutics (ENGN) posted quarterly Other Accumulated Expenses of $953000.0 for Q2 2026, up 87.6% year-over-year from $508000.0 in Q2 2025, and up 317.98% quarter-over-quarter from $228000.0 in Q1 2026.
enGene Therapeutics (ENGN) Other Accumulated Expenses (2023 - 2026) Analysis & Trends
enGene Therapeutics (ENGN) has reported Other Accumulated Expenses for 4 consecutive years, with $953000.0 the latest figure, recorded in Q2 2026.
- In Q2 2026, Other Accumulated Expenses rose 87.6% year-over-year to $953000.0; the TTM figure through Apr 2026 stood at $953000.0 (up 87.6% YoY), while the FY2025 annual figure was $577000.0, up 156.44% from the prior year.
- Other Accumulated Expenses improved to $953000.0 in Q2 2026 per ENGN's latest filing, from $228000.0 in the prior quarter.
- Across five years, Other Accumulated Expenses topped out at $953000.0 in Q2 2026 and bottomed at $57000.0 in Q1 2024.
- Historically, Other Accumulated Expenses has averaged $409363.6 across 4 years, with a median of $403000.0 in 2024.
- Annual changes were most pronounced in 2025 — Other Accumulated Expenses soared 877.19% — and 2026, when it sank 59.07%.
- enGene Therapeutics' Other Accumulated Expenses stood at $113000.0 in 2023, then jumped by 99.12% to $225000.0 in 2024, then surged by 156.44% to $577000.0 in 2025, then soared by 65.16% to $953000.0 in 2026.
- Business Quant data shows ENGN's Other Accumulated Expenses at $953000.0 in Q2 2026, $228000.0 in Q1 2026, and $577000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | enGene Therapeutics | 124.11 Mn | 124.11 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 953,000.00 |
| Jan 31, 2026 | 228,000.00 |
| Oct 31, 2025 | 577,000.00 |
| Jul 31, 2025 | 610,000.00 |
| Apr 30, 2025 | 508,000.00 |
| Jan 31, 2025 | 557,000.00 |
| Oct 31, 2024 | 225,000.00 |
| Jul 31, 2024 | 403,000.00 |
| Apr 30, 2024 | 272,000.00 |
| Jan 31, 2024 | 57,000.00 |
| Oct 31, 2023 | 113,000.00 |